PORTLAND, Ore.--(BUSINESS WIRE)--PRESS RELEASE--Conception Nurseries, a cannabis micropropagation company that has been quietly developing cannabis tissue culture clones for nearly two years, is now launching publicly. Conception is bringing tissue culture technology, a crucial component of industrial scale agriculture, to the cannabis industry. With tissue culture micropropagation, Conception produces plantlets that are free of pathogens and have exceptional vigor, at a cost-per-plant below producers' in-house costs.
Conception is led by Chief Executive Officer Kevin Brooks. Kevin most recently served as the CEO of Connected Cannabis, one of the largest vertically integrated cannabis companies in California. Before entering the cannabis industry, Kevin spent 15 years as an executive in Silicon Valley supporting companies through multiple successful exits.
In partnership with both Phylos, a cannabis agricultural genomics company, and CropOne, one of the largest and highest yielding vertical agriculture companies, Conception provides cultivators with next-generation, targeted cannabis varieties customized for the needs of consumers and cultivators.
Through its partnership with Phylos, Conception’s tissue culture clones will each be genetically tested and registered with Phylos. A unique genetic ID is assigned to each plant tested, and includes a report revealing identical clone matches and how they’re related to varieties around the world.
Through its technology partnership with CropOne, Conception will use the world’s leading controlled-environment agriculture platform and plantlet development technology to ensure plantlets are pathogen free as well as consistent, vigorous growers.
Conception will be launching its Series A funding and facility rollout plans.
